The controversy over Sirtris drugs reached a tipping point in January with a publication by Pfizer researchers led by Kay Ahn showing that resveratrol activates SIRT1 only when linked to a ...

Ken Garber reports. At an investors' meeting in January, Sirtris Pharmaceuticals' CEO Christoph Westphal announced that the company's diabetes drug, SRT501, was showing signs of efficacy in a ...

native already had the resume of a biotech wunderkind: she graduated from the University of Oxford with an MD and PhD, went on to serve as vice president of Cambridge-based Sirtris Pharmaceuticals ...